Drug Profile


Alternative Names: ACH-0142684; ACH-2684; Neceprevir

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Achillion Pharmaceuticals
  • Class Amides; Antivirals; Piperidines; Pyrroles; Quinolines; Small molecules; Thiazoles
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 01 May 2014 Achillion completes a phase I trial in Hepatitis C (Combination therapy; In volunteers) in New Zealand (ACTRN12614000102673)
  • 03 Feb 2014 Phase-I clinical trials in Hepatitis C (Combination therapy; In volunteers) in New Zealand (PO)
  • 20 Feb 2013 Achillion Pharmaceuticals completes a phase I trial in Hepatitis C infections in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top